• David W Jenkins, Christopher J Langmead, Andrew A Parsons, and Paul J Strijbos.
• Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, Cold Harbour Road, Harlow, Essex CM 19 5AW, UK. david.jenkins@astrazeneca.com
• Neurosci. Lett. 2004 Aug 19;366(3):241-4.

AbstractCalcitonin gene-related peptide (CGRP) released from trigeminal primary afferents has been implicated in the pathophysiology of migraine. Here, we have used an in vitro slice preparation to investigate its release from nerve terminals in the rat trigeminal nucleus caudalis. Extracellular-calcium dependent CGRP release was stimulated by both capsaicin and neuronal depolarization with KCl. The capsaicin (1 microM)-evoked CGRP release was blocked by capsazepine and was also attenuated in the presence of the cyclooxygenase inhibitor, indomethacin, an effect that was reversed when slices were stimulated with capsaicin in the presence of the cyclooxygenase metabolite, prostaglandin E(2). Taken together, these data further highlight the importance of prostaglandins as enhancers of neuropeptide release and suggest that CGRP released from the central terminals of trigeminal neurones has the potential to be involved in the transmission of nociceptive information of relevance to migraine headache.

27 keywords...

hide…